Clinical application and research progress of Xpert MTB/RIF Ultra and Xpert MTB/RIF tests

doi:10.3969/j.issn.1000-6621.2018.07.020

Abstract

Abstract:

Tuberculosis (TB) is one of the leading infectious diseases worldwide. As a rapid nucleic acid amplification test, Xpert MTB/RIF (Xpert) assay can detect mycobacteria bacilli and rifampicin resistance simulta-neously, and provide reliable information for TB diagnosis and treatment due to its high sensitivity and specificity. However, Xpert also demonstrated some imperfections during the clinical practice. Xpert MTB/RIF Ultra (Xpert Ultra) assay is a next-generation assay of Xpert, WHO recommended it in March, 2007. In contrast to Xpert, Ultra has acquired increased sensitivity with paucibacillary specimens collected from patients with extra-pulmonary TB, TB/HIV co-infection or pediatric TB, which is of great significance for regimen establishment. In this review, the limitation of Xpert, the similarity and difference between Xpert and Xpert Ultra are discussed, which will throw light on the value of Xpert Ultra’s clinical application.

Key words: Tuberculosis, Nucleic acid amplification techniques, Early diagnosis, Review literature as topic

Shu-qi WANG,Hai-rong HUANG,Gui-rong WANG. Clinical application and research progress of Xpert MTB/RIF Ultra and Xpert MTB/RIF tests[J]. Chinese Journal of Antituberculosis, 2018, 40(7): 776-780. doi: 10.3969/j.issn.1000-6621.2018.07.020

References 37

[1]	World Health Organization . Use of high burden country lists for TB by WHO in the post 2015. Geneva: World Health Organization, 2015.
[2]	Mulder C, Mgode GF, Ellis H , et al. Accuracy of giant African pouched rats for diagnosing tuberculosis: comparison with culture and Xpert ^® MTB/RIF . Int J Tuberc Lung Dis, 2017,21(11):1127-1133.
[3]	Campos LC, Rocha MV, Willers DM , et al. Characteristics of Patients with Smear-Negative Pulmonary Tuberculosis (TB) in a Region with High TB and HIV Prevalence. PLoS One, 2016,11(1):e0147933. doi: 10.1371/journal.pone.0147933 URL
[4]	World Health Organization . Global tuberculosis report 2017. Geneva: World Health Organization, 2017.
[5]	Tostmann A, Kik SV, Kalisvaart NA , et al. Tuberculosis transmission by patients with smear-negative pulmonary tuberculosis in a large cohort in the Netherlands. Clin Infect Dis, 2008,47(9):1135-1142. doi: 10.1086/594992 URL
[6]	World Health Organization . Xpert MtB/RIF assay for the dia-gnosis of pulmonary and extrapulmonary TB in adults and children. Geneva: World Health Organization, 2014.
[7]	Helb D, Jones M, Story E , et al. Rapid Detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. J Clin Microbiol, 2010,48(1):229-237. doi: 10.1128/JCM.01463-09 URL
[8]	García-Basteiro AL, Saavedra B, Cobelens F . The Good,the Bad and the Ugly of the Next-Generation Xpert Mtb/Rif ^® Ultra Test for Tuberculosis Diagnosis . Arch Bronconeumol, 2017,53(12):665-666.
[9]	Steingart KR, Schiller I, Horne DJ , et al.Xpert ^® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev, 2014,( 1):CD009593.
[10]	Akanbi MO, Achenbach C, Taiwo B , et al. Evaluation of gene Xpert for routine diagnosis of HIV-associated tuberculosis in Nigeria: A prospective cohort study. BMC Pulm Med, 2017,17(1):87. doi: 10.1186/s12890-017-0430-6 URL
[11]	Lawn SD, Brooks SV, Kranzer K , et al. Screening for HIV-associated tuberculosis and rifampicin resistance before antire-troviral therapy using the Xpert MTB/RIF assay: a prospective study. PLoS Med, 2011,8(7):e1001067. doi: 10.1371/journal.pmed.1001067 URL
[12]	Sohn H, Aero AD, Menzies D , et al. Xpert MTB/RIF testing in a low tuberculosis incidence, high-resource setting: limitations in accuracy and clinical impact. Clin Infect Dis, 2014,58(7):970-976. doi: 10.1093/cid/ciu022 URL
[13]	Yuan M, Lyu Y, Chen ST , et al. Evaluation of Xpert MTB/RIF for the Diagnosis of Extrapulmonary Tuberculosis in China. Biomed Environ Sci, 2016,29(8):599-602.
[14]	Maynard-Smith L, Larke N, Peters JA , et al. Diagnostic accuracy of the Xpert MTB/RIF assay for extrapulmonary and pulmonary tuberculosis when testing non-respiratory samples: a systematic review. BMC Infect Dis, 2014,14:709. doi: 10.1186/s12879-014-0709-7 URL
[15]	Rice JP, Seifert M, Moser KS , et al. Performance of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis and rifampin resistance in a low-incidence, high-resource setting. PLoS One, 2017,12(10):e0186139. doi: 10.1371/journal.pone.0186139 URL
[16]	Albert H, Nathavitharana RR, Isaacs C , et al. Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt and how can we do better? Eur Respir J, 2016,48(2):516-525. doi: 10.1183/13993003.00543-2016 URL
[17]	Huang H, Zhang Y, Li S , et al. Rifampicin Resistance and Multidrug-Resistant Tuberculosis Detection Using Xpert MTB/RIF in Wuhan, China: A Retrospective Study. Microb Drug Resist, 2017. In press.
[18]	Zetola NM, Shin SS, Tumedi KA , et al. Mixed Mycobacterium tuberculosis complex infections and false-negative results for rifampin resistance by GeneXpert MTB/RIF are associated with poor clinical outcomes. J Clin Microbiol, 2014,52(7):2422-2429. doi: 10.1128/JCM.02489-13 URL
[19]	Rufai SB, Kumar P, Singh A , et al. Comparison of Xpert MTB/RIF with line probe assay for detection of rifampin-monoresistant Mycobacterium tuberculosis. J Clin Microbiol, 2014,52(6):1846-1852. doi: 10.1128/JCM.03005-13 URL
[20]	Köser CU, Feuerriegel S, Summers DK , et al. Importance of the genetic diversity within the Mycobacterium tuberculosis complex for the development of novel antibiotics and diagnostic tests of drug resistance. Antimicrob Agents Chemother, 2012,56(12):6080-6087. doi: 10.1128/AAC.01641-12 URL
[21]	Cayci YT, Bilgin K, Coban AY , et al. An evaluation of false-positive rifampicin resistance on the Xpert MTB/RIF. Mem Inst Oswaldo Cruz, 2017,112(11):756-759. doi: 10.1590/0074-02760170051 URL pmid: 5661898
[22]	Williamson DA, Basu I, Bower J , et al. An evaluation of the Xpert MTB/RIF assay and detection of false-positive rifam-picin resistance in Mycobacterium tuberculosis. Diagn Microbiol Infect Dis, 2012,74(2):207-209. doi: 10.1016/j.diagmicrobio.2012.06.013 URL
[23]	World Health Organization . WHO meeting report of a technical expert consultation: A multicentre non-inferiority analysis of Xpert MTB/RIF ultra compared to Xpert MTB/RIF, 2017. Geneva: World Health Organization, 2017.
[24]	Bahr NC, Nuwagira E, Evans EE , et al. Team A-CT. Diagnostic accuracy of Xpert MTB/RIF Ultra for tuberculous meningitis in HIV-infected adults: a prospective cohort study. Lancet Infect Dis, 2018,18(1):68-75. doi: 10.1016/S1473-3099(17)30474-7 URL
[25]	Kendall EA, Schumacher SG, Denkinger CM , et al. Estimated clinical impact of the Xpert MTB/RIF Ultra cartridge for diagnosis of pulmonary tuberculosis: A modeling study. PLoS Med, 2017,14(12):e1002472. doi: 10.1371/journal.pmed.1002472 URL
[26]	Chakravorty S, Simmons AM, Rowneki M , et al. The new Xpert MTB/RIF Ultra: improving detection of Mycobacterium tuberculosis and resistance to rifampin in an assay suitable for point-of-care testing.MBio, 2017, 8(4): pii:e00812-817.
[27]	Chakravorty S, Kothari H, Aladegbami B , et al. Rapid, high-throughput detection of rifampin resistance and heteroresistance in Mycobacterium tuberculosis by use of sloppy molecular beacon melting temperature coding. J Clin Microbiol, 2012,50(7):2194-2202. doi: 10.1128/JCM.00143-12 URL
[28]	World Health Organization . Frequently asked questions about the WHO Technical Expert Consultation findings on Xpert ^® MTB/RIF Ultra . Geneva: World Health Organization, 2017.
[29]	Foundation for Innovative New Diagnostics( FIND). A multicentre non-inferiority diagnostic accuracy study of the ultra assay compared to the Xpert MTB/RIF assay. Geneva: Foundation for Innovative New Diagnostics, 2017.
[30]	Cox HS, Mbhele S, Mohess N , et al. Impact of Xpert MTB/RIF for TB diagnosis in a primary care clinic with high TB and HIV prevalence in South Africa: a pragmatic randomised trial. PLoS Med, 2014,11(11):e1001760. doi: 10.1371/journal.pmed.1001760 URL
[31]	Churchyard GJ, Stevens WS, Mametja LD , et al. Xpert MTB/RIF versus sputum microscopy as the initial diagnostic test for tuberculosis: a cluster-randomised trial embedded in South African roll-out of Xpert MTB/RIF. Lancet Glob Health, 2015,3(8):e450-457. doi: 10.1016/S2214-109X(15)00100-X URL
[32]	Durovni B , Saraceni V,van den Hof S,et al. Correction:Impact of Replacing Smear Microscopy with Xpert MTB/RIF for Diagnosing Tuberculosis in Brazil: A Stepped-Wedge Cluster-Randomized Trial. PLoS Med, 2015,12(12):e1001928. doi: 10.1371/journal.pmed.1001928 URL
[33]	Sachdeva KS, Raizada N, Sreenivas A , et al. Use of Xpert MTB/RIF in Decentralized Public Health Settings and Its Effect on Pulmonary TB and DR-TB Case Finding in India. PLoS One, 2015,10(5):e0126065. doi: 10.1371/journal.pone.0126065 URL
[34]	张爱梅, 李峰, 刘旭辉 , 等. 结核分枝杆菌/利福平耐药实时荧光定量核酸扩增检测在肺外结核中的诊断价值. 中华传染病杂志, 2016,34(3):174-179. doi: 10.3760/cma.j.issn.1000-6680.2016.01.009 URL
[35]	孙庆燕, 孙冰, 张娟 . GeneXpert MTB/RIF在诊断肺内及肺外结核病的应用评价. 医学检验与临床, 2017,28(10):27-30.
[36]	张炜平, 秦超 . 支气管肺泡灌洗液 Xpert MTB/RIF检验在痰涂阴肺结核发现中的价值. 中国生化药物杂志, 2017,37(2):302-304. doi: 10.3969/j.issn.1005-1678.2017.02.095 URL
[37]	张海晴, 刘成永, 周冬青 , 等. GeneXpert MTB/RIF系统在结核性胸膜炎快速诊断中应用价值. 北京医学, 2016,38(7):739-741.